RAC1$^{P29S}$ induces a mesenchymal phenotypic switch via serum response factor to promote melanoma development and therapy resistance by Lionarons, Daniël A et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
RAC1P29S induces a mesenchymal phenotypic switch via serum response
factor to promote melanoma development and therapy resistance
Lionarons, Daniël A ; Hancock, David C ; Rana, Sareena ; East, Philip ; Moore, Christopher ; Murillo,
Miguel M ; Carvalho, Joana ; Spencer-Dene, Bradley ; Herbert, Eleanor ; Stamp, Gordon ; Damry,
Djamil ; Calado, Dinis P ; Rosewell, Ian ; Fritsch, Ralph ; Neubig, Richard R ; Molina-Arcas, Miriam ;
Downward, Julian
Abstract: RAC1 P29 is the third most commonly mutated codon in human cutaneous melanoma, after
BRAF V600 and NRAS Q61. Here, we study the role of RAC1P29S in melanoma development and
reveal that RAC1P29S activates PAK, AKT, and a gene expression program initiated by the SRF/MRTF
transcriptional pathway, which results in a melanocytic to mesenchymal phenotypic switch. Mice with
ubiquitous expression of RAC1P29S from the endogenous locus develop lymphoma. When expressed only
in melanocytes, RAC1P29S cooperates with oncogenic BRAF or with NF1-loss to promote tumorigenesis.
RAC1P29S also drives resistance to BRAF inhibitors, which is reversed by SRF/MRTF inhibitors. These
findings establish RAC1P29S as a promoter of melanoma initiation and mediator of therapy resistance,
while identifying SRF/MRTF as a potential therapeutic target.
DOI: https://doi.org/10.1016/j.ccell.2019.05.015
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-184569
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Lionarons, Daniël A; Hancock, David C; Rana, Sareena; East, Philip; Moore, Christopher; Murillo,
Miguel M; Carvalho, Joana; Spencer-Dene, Bradley; Herbert, Eleanor; Stamp, Gordon; Damry, Djamil;
Calado, Dinis P; Rosewell, Ian; Fritsch, Ralph; Neubig, Richard R; Molina-Arcas, Miriam; Downward,
Julian (2019). RAC1P29S induces a mesenchymal phenotypic switch via serum response factor to promote
melanoma development and therapy resistance. Cancer Cell, 36(1):68-83.e9.
DOI: https://doi.org/10.1016/j.ccell.2019.05.015
Article
RAC1P29S Induces a Mesenchymal Phenotypic
Switch via Serum Response Factor to Promote
Melanoma Development and Therapy Resistance
Graphical Abstract
Highlights
d RAC1P29S activates PAK, AKT, and the SRF/MRTF
transcription program in melanocytes
d RAC1P29S induces a melanocytic to mesenchymal transition
through SRF/MRTF and PAK
d RAC1P29S cooperates with BRAF mutation or NF1 deletion to
promote melanomagenesis
d RAC1P29S induces resistance to BRAF inhibitors through
SRF/MRTF
Authors
Dani€el A. Lionarons, David C. Hancock,
Sareena Rana, ..., Richard R. Neubig,
Miriam Molina-Arcas,
Julian Downward
Correspondence
miriam.molina@crick.ac.uk (M.M.-A.),
julian.downward@crick.ac.uk (J.D.)
In Brief
RAC1P29S is a common mutation in
human cutaneous melanoma. Lionarons
et al. show that RAC1P29S induces a
melanocytic to mesenchymal switch via
an SRF/MRTF-mediated gene expression
program, cooperates with BRAF in
melanomagenesis, and drives BRAF
inhibitor resistance, which is reversed by
SRF/MRTF inhibition.
Lionarons et al., 2019, Cancer Cell 36, 68–83
July 8, 2019 ª 2019 The Author(s). Published by Elsevier Inc.
https://doi.org/10.1016/j.ccell.2019.05.015
Cancer Cell
Article
RAC1P29S Induces a Mesenchymal Phenotypic Switch
via Serum Response Factor to Promote Melanoma
Development and Therapy Resistance
Dani€el A. Lionarons,1 David C. Hancock,1 Sareena Rana,1,6 Philip East,2 Christopher Moore,1 Miguel M. Murillo,1,6
Joana Carvalho,3 Bradley Spencer-Dene,3 Eleanor Herbert,3,7 Gordon Stamp,3 Djamil Damry,4 Dinis P. Calado,4
Ian Rosewell,5 Ralph Fritsch,1,8 Richard R. Neubig,9 Miriam Molina-Arcas,1,* and Julian Downward1,6,10,*
1Oncogene Biology, Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
2Bioinformatics & Biostatistics, Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
3Experimental Histopathology, Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
4Immunity & Cancer Laboratories, Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
5Genetic Manipulation Service, Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
6Lung Cancer Group, Division of Molecular Pathology, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK
7Royal Veterinary College, Hatfield AL9 7TA, UK
8Universit€atsklinikum Freiburg, Freiburg 79106, Germany
9Michigan State University, East Lansing, MI 48824, USA
10Lead Contact
*Correspondence: miriam.molina@crick.ac.uk (M.M.-A.), julian.downward@crick.ac.uk (J.D.)
https://doi.org/10.1016/j.ccell.2019.05.015
SUMMARY
RAC1 P29 is the third most commonly mutated codon in human cutaneous melanoma, after BRAF V600 and
NRAS Q61. Here, we study the role of RAC1P29S in melanoma development and reveal that RAC1P29S
activates PAK, AKT, and a gene expression program initiated by the SRF/MRTF transcriptional pathway,
which results in a melanocytic to mesenchymal phenotypic switch. Mice with ubiquitous expression of
RAC1P29S from the endogenous locus develop lymphoma. When expressed only in melanocytes, RAC1P29S
cooperates with oncogenic BRAF or with NF1-loss to promote tumorigenesis. RAC1P29S also drives
resistance to BRAF inhibitors, which is reversed by SRF/MRTF inhibitors. These findings establish RAC1P29S
as a promoter of melanoma initiation and mediator of therapy resistance, while identifying SRF/MRTF as a
potential therapeutic target.
INTRODUCTION
Melanoma is a potentially lethal form of skin cancer responsible
for the death of 55,500 people per year globally, with incidence
rising rapidly, especially in Western countries (Eggermont
et al., 2014). Chronic sun-exposure is the most important cause
of melanoma, with UV radiation-induced mutations, particularly
in tumor suppressor genes, contributing to the development of
the disease (Viros et al., 2014). The commonest oncogenic driver
mutation is BRAFV600E, present in up to 50% of cases, followed
by NRAS codon 61, mutated in about 20% of melanomas. The
third most common mutation lies in the gene encoding the
RHO family small GTPase RAC1. The RAC1 P29S mutation is
present in around 4% of melanomas. This amino acid change
arises from a UV radiation-induced C > T transition at a dipyrimi-
dine site. The P29S mutation activates the biological activity of
RAC1 by promoting guanine nucleotide exchange, hence
increasing the relative ratio of active GTP-bound RAC1 to
Significance
Metastatic melanoma is a lethal disease, partly due to rapid acquisition of resistance to therapy. Using genetically engi-
neeredmouse models, we demonstrate that the activating RAC1P29S mutation, present in up to 4% of melanoma cases, co-
operates with BRAF as a driver of melanoma initiation and promotes BRAF inhibitor resistance. Since clinical inhibitors of
RAC1 are not currently available, we systematically evaluated RAC1P29S signaling and the functional significance of its
downstream effector pathways. Our findings suggest that the critical RAC1 effector in melanoma is the transcription factor
complex SRF/MRTF, which initiates a switch to a mesenchymal-like state characterized by therapy resistance. Therapeutic
targeting of SRF/MRTF may have potential to reverse BRAF inhibitor resistance in melanoma patients bearing the onco-
genic RAC1P29S mutation.
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inactive GDP-bound RAC1 (Hodis et al., 2012; Krauthammer
et al., 2012). The potential importance of RAC1 function in
melanoma is further underlined by the discovery of frequent
alterations in PREX2, and to a lesser extent PREX1, which are
guanine nucleotide exchange factors for RAC1 (Berger et al.,
2013). In at least some cases, truncating mutations in PREX2
have been shown to result in gain of function in terms of RAC1
activation (Lissanu Deribe et al., 2016). Overall, 30% of mela-
nomas show alterations in either PREX1 or PREX2, although
the functional significance of most of these individual changes
has not been tested and may not all be mediated through
RAC1 signaling.
Despite frequent mutational activation of RAC1 and its regula-
tors in melanoma, the functional implications for the disease are
poorly understood. As expected for a fast-cycling mutant pro-
tein, RAC1P29S has been reported to show increased binding
to direct effectors such as PAK1, MLK3, and the WAVE complex
(Chen et al., 2017; Hodis et al., 2012; Kawazu et al., 2013; Kraut-
hammer et al., 2012; Watson et al., 2014). Overexpression of
RAC1P29S increased cell proliferation, migration, anchorage-in-
dependent growth, and promoted growth of transplanted cells
in nude mice. Varying and relatively modest effects of RAC1P29S
on MAPK activation have been reported. In addition, RAC1P29S
has been reported to promote the expression of the immune
checkpoint ligand PD-L1 in cells (Vu et al., 2015). Finally, it was
reported that ectopic expression of RAC1P29S in BRAF mutant
melanoma cells generates resistance to BRAF inhibition and
that three patients with the mutation responded particularly
poorly to a BRAF inhibitor (Van Allen et al., 2014).
Genetically engineered mouse models addressing the role of
RAC1 in melanomagenesis have yet to be reported. However,
deletion of Prex1, encoding an upstream activator of RAC1,
has been reported to suppress migration and metastasis in a
melanoma model (Lindsay et al., 2011). In addition, mice with
inducible overexpression of the activated PREX2E824* mutant
in melanocytes showed increased melanomagenesis (Lissanu
Deribe et al., 2016).
Overall, there is a considerable body of evidence pointing to an
important role for RAC1 signaling in melanoma, but the nature of
its function remains largely unclear.Which downstream effectors
of RAC1might be important in melanoma is not known, although
a recent report has highlighted a potential role for PAK in a zebra-
fish model and in human melanoma cell lines (Araiza-Olivera
et al., 2018). A greater understanding of the role of RAC1P29S in
melanoma and the effector pathways involvedmay provide ther-
apeutic targets.
RESULTS
Expression of RAC1P29S Promotes Cell Survival in the
Absence of Growth Factors or Anchorage
To investigate RAC1P29S signaling, we stably expressed
RAC1WT, RAC1P29S, and the constitutively active mutant
RAC1Q61L in MCF10A immortalized breast epithelial cells (Fig-
ure S1A). RAC1 codon 61 mutations are not found in human
melanoma, but RAC1Q61L served as a control for increased
RAC1 signaling. RAC1P29S promoted survival when cells were
starved of growth factors, whereas proliferation in normal me-
dium was unaffected (Figures S1B and S1C). When seeded in
soft agar, RAC1P29S enabled the formation of spheres (Fig-
ure S1D). Constitutively active RAC1Q61L promoted sphere for-
mation to a lesser extent than RAC1P29S, while suppressing the
2D proliferation rate, which may explain why this mutation is
not found in human melanoma.
To study the signaling effects of RAC1P29S in a temporally
controlled manner, we developed an ER-RAC1P29S fusion pro-
tein system that can be acutely activated by treatment with 4-hy-
droxytamoxifen (4OHT) (Figure 1A). Activation of ER-RAC1P29S
led to increased binding and phosphorylation of the RAC1
effector PAK1 in bothMCF10A cells and themouse immortalized
melanocyte cell line melan-a (Figures 1B, 1C and S1E), but
caused extracellular signal-regulated kinase (ERK) activation
only transiently and weakly (Figures 1C, 1D, S1E, and S1F), in
contrast to ER-RAC1Q61L (Figure S1E). Differential activation of
the MAPK pathway was not associated with ER-RAC1 protein
expression levels, which were similar (Figure S1G). Melanocytes
with ER-RAC1P29S underwent a morphological change upon
4OHT treatment, with generalized extension of lamellipodia (Fig-
ure 1E) and increased peripheral staining of polymerized actin
(Figure S1H). Activation of ER-RAC1P29S in melanocytes pro-
moted survival when cells were starved of growth factors and
enabled sphere formation when seeded in soft agar (Figures
1F and 1G), with only minor effects on proliferation in 2D culture
(Figure S1I). In low adhesion conditions, activated ER-RAC1P29S
promoted cell survival (Figure S1J). When starved of growth
factors, activated ER-RAC1P29S suppressed apoptosis (Fig-
ure 1H). Knockdown of RAC1 reversed the effects on viability
and apoptosis (Figures 1F–1H).
We have thus developed an ER fusion protein system that
allows temporal control of RAC1P29S activation in melanocytes,
revealing that RAC1P29S protects against apoptosis and pro-
vides cells with a survival advantage when deprived of growth
factors or anchorage.
RAC1P29S Activates an SRF/MRTF Transcriptional
Program and Drives Melanocytes toward a
Mesenchymal State
A reverse-phase protein arraywas employed to study the cellular
signals transmitted by RAC1P29S. We found that AKT was
increasingly phosphorylated upon ER-RAC1P29S activation in
melanocytes (Figures 2A, 2B, and S2A). Conversely, small
hairpin RNA (shRNA)-mediated depletion of the endogenous
RAC1P29S in a human melanoma cell line suppressed phosphor-
ylation of AKT (Figure S2B). In both of these systems, we found
no evidence that RAC1P29S signals via the MAPK pathway (Fig-
ures S2B and S2C).
Next, we explored effects of RAC1P29S signaling on the tran-
scriptome of melanocytes. Activation of ER-RAC1P29S induced
numerous gene expression changes in melanocytes (Figure 2C).
After 4 h, targets of the transcription factor SRF were heavily
enriched among the upregulated genes, while no other transcrip-
tion factor was significantly linked to the gene expression
changes (Figures 2D–2F). SRF can be activated via either the
ternary complex factor (TCF) or myocardin-related transcription
factor (MRTF) co-factor. TCFs are regulated by MAPK signaling,
whileMRTF is inhibited bymonomeric actin and can be activated
by RHO GTPases that polymerize actin and thereby relieve the
inhibition (Esnault et al., 2014; Miralles et al., 2003). When
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Figure 1. Effect of Activation of RAC1P29S on Survival of Melanocytes
(A) Schematic of the ER-RAC1P29S fusion protein system. ER, estrogen receptor; 4OHT, 4-hydroxytamoxifen; HSP, heat shock protein.
(B) RAC1-GTP assay in MCF10A cells (left) andmouse melanocyte cell line melan-a (right) stably expressing ER-RAC1P29S. Cells were treated with 500 nM 4OHT
for 24 h and ER-RAC1P29S binding to the PAK1 RAC1 binding domain was assessed using a pull-down assay.
(C) PAK1/2 and ERK1/2 phosphorylation by ER-RAC1P29S in melanocytes. Cells were treated with 500 nM 4OHT for 24 h.
(D) Quantification of phospho-PAK1/2 and phospho-ERK1/2 levels detected by immunoblotting, normalized using vinculin loading control (n = 3 or more in-
dependent experiments); t test versus 0 h was used with Holm-Sidak correction for multiple testing; *p < 0.05, ***p < 0.001; n.s., not statistically significant.
(E) Morphological changes induced by ER-RAC1P29S activation in melan-a melanocytes treated with 500 nM 4OHT.
(F) Viability of melan-a melanocytes with ER-RAC1P29S in growth factor-reduced medium (fetal calf serum [FCS] 0.25%, 12-O-tetradecanoylphorbol-13-acetate
[TPA]-free). Cells were treated with 1 mM 4OHT and viability was quantified using CellTiter-Glo (n = 3 independent experiments); t test was used for statistical
comparison.
(G) Soft agar sphere formation of melan-a melanocytes with activated ER-RAC1P29S. Cells were grown in full medium containing 1 mM 4OHT for 3 weeks before
staining, imaging, and automated counting (n = 3 biological replicates).
(H) Effect of activation of ER-RAC1P29S on apoptosis in melan-a melanocytes. Cells were treated with 1 mM 4OHT. Cleaved caspase-3 was quantified and
normalized to cell viability (n = 2 independent experiments, three biological replicates per experiment).
Bars represent means ± SD. See also Figure S1.
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Figure 2. Effect of Acute Activation of RAC1P29S in Melanocytes on AKT and SRF/MRTF Effector Pathways
(A) Reverse-phase protein array using ER-RAC1P29S melanocytes after RAC activation, expressed as a scatterplot with p values and log2 fold change compared
with 0 h control (means from 3 independent experiments).
(B) Densitometric quantification of phospho-AKT levels determined by immunoblotting, normalized to total AKT levels. Melan-a ER-RAC1P29S cells were treated
with 4OHT at 500 nM (n = 4 independent experiments, one representative immunoblot shown); t test was used for statistical comparison.
(C) RNA sequencing (RNA-seq) in ER-RAC1P29S melanocytes, expressed as scatterplots for empty vector cells and ER-RAC1P29S cells treated with 500 nM
4OHT. Blue dots represent values statistically different to 0 h values (false discovery rate [FDR] 5%).
(D) Transcription factor target enrichment analysis of gene expression changes in melanocytes 4 h after activation of ER-RAC1P29S. Gene set enrichment analysis
(GSEA) using the transcription factor target gene sets from the MSigDB database (Broad). NES, normalized enrichment score.
(E) GSEA plot of the direct SRF target gene set from Esnault et al. (2014), using all genes expressed in the ER-RAC1P29S melanocytes at 4 versus 0 h 4OHT
treatment.
(F) Normalized RNA-seq read counts of canonical SRF/MRTF targets (n = 3 independent experiments).
(G) Pathway enrichment analysis of gene expression changes in melanocytes 40 h after activation of ER-RAC1P29S. GSEA using the curated hallmark gene set
collection from MSigDB.
(H) GSEA plot of the epithelial-to-mesenchymal transition (EMT) hallmark gene set fromMSigDB using gene expression differences in ER-RAC1P29Smelanocytes
treated for 40 h with 4OHT compared with 0 h control.
(I) Relative mRNA of mesenchymal markers in melanocytes with activated ER-RAC1P29S, quantified using RNA-seq (n = 3 independent experiments).
(legend continued on next page)
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assessing the relative contribution of TCF versus MRTF signa-
tures in our gene expression data, we found that MRTF signa-
tures were particularly enriched and any enrichment effect of
TCF signatures could be attributed to target overlap with
MRTF (Figures S2D–S2H).
Forty hours after activating ER-RAC1P29S, many potentially
secondary and tertiary gene expression changes were
observed. Pathway enrichment analysis revealed that genes
involved in epithelial-to-mesenchymal transition (EMT) were
most strongly enriched among upregulated genes (Figures 2G–
2I). EMT can be viewed a misnomer in this context, given that
melanocytes are not epithelial-lineage cells. We searched for
EMT-driving transcription factors among upregulated genes
and indeed found that the SRF/MRTF targets Snai2 and Jun
were upregulated, suggesting a link between SRF/MRTF activa-
tion and promotion of a mesenchymal-like state (Figure S2I). To
establish a causal relationship, we activated ER-RAC1P29S in the
presence of the specific SRF/MRTF inhibitors CCG-1423 and
CCG-203971 (Haak et al., 2017). This suppressed the induction
of Snai2 and Jun, and mesenchymal marker gene and protein
expression (Figures 2J, S2J, and S2K), indicating that ER-
RAC1P29S initiates a melanocytic to mesenchymal transition
through SRF/MRTF. Similar results were obtained when MRTF
was depleted using RNAi (Figure S2L). Depletion of the EMT
transcription factors Snai2 and Jun significantly reduced the
survival ability of melanocytes with activated RAC1P29S (Fig-
ure S2M). Similar to results at 4 h, transcription factor target
enrichment analysis demonstrated that SRF was the dominant
driver of gene expression changes following 40 h of ER-
RAC1P29S activation (Figure S2N). To assess the effect of PAK
on activation of SRF/MRTF and the transition to a mesenchymal
identity, we used the PAK inhibitor G-5555 and quantified gene
expression of canonical SRF/MRTF targets and mesenchymal
markers. We observed that PAK is not involved in the activation
of SRF/MRTF, but does contribute to the transition to a mesen-
chymal identity (Figure S2O).
Taken together, unbiased proteomic and transcriptomic ana-
lyses revealed that melanocytic ER-RAC1P29S activates AKT
and initiates a shift toward a more mesenchymal transcriptional
state via SRF/MRTF and PAK.
Endogenous RAC1P29S in Melanocytes Recapitulates
the Effects of ER-RAC1P29S
Conclusions drawn from previous studies regarding the func-
tions of RAC1P29S, including those described above, have relied
on ectopic expression experiments or the comparison between
endogenous RAC1P29S mutant and RAC1WT human melanoma
cell lines, which have other genetic alterations. To enable more
controlled modeling of the impact of endogenous RAC1P29S,
we generated mice carrying a conditional P29S mutation tar-
geted to the endogenous Rac1 locus. A Lox-stop-Lox (LSL)
cassette was inserted upstream of a mutated exon 2, which pro-
duces a null allele in the absence of Cre recombinase and a P29S
mutant allele following exposure to Cre recombinase activity
(Figure 3A). HomozygousRac1LSLP29S was embryonically lethal
in mice lacking Cre, in concordance with results from Rac1
knockout mice (Sugihara et al., 1998) (Figure S3A). We also
observed some degree of lethality in heterozygous mice, indi-
cating that two copies of the wild-type Rac1 allele are required
for optimal development (Figure S3B).
When we isolated mouse embryonic fibroblasts (MEFs) from
Rac1LSLP29S/WT mice crossed onto a ubiquitously expressed
conditional Cre driver (Rosa26-CreER), recombination resulted
in increased binding of RAC1 to its effector PAK1 and elevated
levels of phospho-PAK and phospho-AKT (Figures 3B, 3C, and
S3C). To study the effects of RAC1P29S in amore relevant cellular
context, melanocytes were isolated from Rac1LSLP29S/WT mice
and Rac1WT/WT littermates crossed onto a melanocyte-specific
inducible Cre (Tyr-CreER; Figure S3D). As observed in MEFs
and in ER-RAC1P29S melanocytes, phosphorylation of PAK and
AKT was consistently increased in cells expressing RAC1P29S,
while phospho-ERK levels were not (Figures 3D and S3E). Three
melanocyte cultures expressing endogenous RAC1P29S and
three RAC1WT cultures were subjected to mRNA sequencing to
investigate effects on gene expression. Targets of SRF/MRTF
were most enriched among upregulated genes compared with
other transcription factors (Figures 3E–3G). In addition, we de-
tected a strong presence of the EMT gene expression signature
and commonly used mesenchymal markers were increased at
the mRNA and protein levels (Figures 3H and S3E–S3G). SRF/
MRTF inhibition reduced expression of the mesenchymal
markers vimentin and N-cadherin in mouse melanocytes with
endogenous RAC1P29S (Figures 3I and S3H).
In summary, melanocyte cultures expressing RAC1P29S from
the endogenous locus showed increased activation of PAK,
AKT, and SRF/MRTF, and displayed a more mesenchymal
gene expression profile, confirming our findings made with
ectopic expression systems.
Melanocytes and Melanoma Cells Driven by RAC1P29S
Depend on AKT and MRTF for Survival
Long-term culture of melanocytes in full medium demonstrated
that RAC1P29S does not alter their rate of proliferation or immor-
talization (Figure S4A). However, endogenous RAC1P29S pro-
moted survival when melanocytes were cultured in the absence
of growth factors or seeded at very low densities (Figures 4A and
S4B). Moreover, we observed increased sphere-forming ability
when the cells were seeded in soft agar (Figure 4B) and protec-
tion against apoptosis when cells were starved of growth factors
and adhesion (Figure S4C).
We interrogated which downstream effectors are used by
RAC1P29S for the promotion of survival in the hope of uncovering
therapeutic targets for P29Smutant RAC1-driven melanoma. To
study this in a systematic manner, we designed a RAC1 effector
RNAi screen. We included genes whose products are known to
directly bind RAC proteins (gene ontology GO:0048365, n = 31);
selected genes whose products are reported to function in
signaling pathways downstream of RAC1 activation (PAK,
(J) Effect of treatment with SRF/MRTF inhibitors on mesenchymal marker induction by ER-RAC1P29S. Cells were pre-treated with 5–10 mM CCG-1423 or
CCG-203971 1 h before 4OHT treatment (1 mM) for 48 h (n = 3 independent experiments); mRNA levels were determined using qPCR and normalized to Gapdh
expression.
For all graphs: bars represent means ± SD. See also Figure S2.
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MAPK, PI3K, SRF, NF-kB, JNK, STAT3, Wnt, and integrin
signaling; n = 53); and genes upregulated in ER-RAC1P29S mela-
nocytes that are associated with cell survival, plus the transcrip-
tion factors suspected to be driving these gene expression
changes (n = 115). Three melanocyte cultures from each Rac1
genotype were transfected with the arrayed custom small
interfering RNA (siRNA) library, grown in growth factor-reduced
medium and assayed for viability 96 h after transfection.
Effective knockdown was suggested by near-complete killing
efficiency for multiple siRNA pools, including Myc, and experi-
mentally verified for the Mkl2 pool (Figure S4D). We particularly
focused on genes that, when depleted, specifically reduced
viability of RAC1P29S melanocytes compared with RAC1WT
counterparts. An siRNA pool targeting RAC1 itself was included
A B C
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Figure 3. Impact of Endogenous RAC1P29S on AKT and SRF/MRTF Activation in Melanocytes and Mesenchymal Phenotype
(A) Schematic of the Rac1LSLP29S allele.
(B) Rosa26-CreER+/–;Rac1LSLP29S/WT and Rosa26-CreER+/–;Rac1WT/WT MEFs were isolated and recombined using 1 mM 4OHT. Activation of RAC1 was as-
sessed using pull-down assay.
(C) Phosphorylation of PAK1/2 and AKT in MEFs upon recombination of the Rac1LSLP29S allele by 4OHT treatment (1 mM).
(D) Phosphorylation of PAK1/2 and AKT in mouse melanocytes with endogenous RAC1P29S. Immunoblot of three independent cultures per genotype is shown.
(E) Transcription factor target enrichment analysis of gene expression changes in melanocytes with endogenous RAC1P29S versus RAC1WT. GSEA was per-
formed using the transcription factor target gene set collection from MSigDB in combination with RNA-seq data of melanocytes from Rac1LSLP29S/WT mice
versus Rac1WT/WT mice (n = 3 independent cultures per genotype).
(F) GSEA results using SRF/MRTF/TCF gene sets from Esnault et al. (2014), was applied on RNA-seq data frommelanocytes cultured with endogenous RAC1P29S
versus RAC1WT. GSEA plot for direct targets of MRTF is shown.
(G) Normalized mRNA read counts of canonical SRF/MRTF targets in melanocytes with endogenous RAC1P29S (n = 3 independent cultures per genotype); Wald
test was applied in combination with Benjamini-Hochberg correction.
(H) GSEA plot of the curated EMT hallmark gene set from MSigDB using RNA-seq data of melanocytes from Rac1LSLP29S/WT mice versus Rac1WT/WT mice (n =
3 independent cultures per genotype).
(I) Effect of SRF/MRTF pathway inhibition onmRNA expression of vimentin in mousemelanocytes with endogenous RAC1P29S. Cells were treated with 10–25 mM
CCG-1423 or CCG-203971 and starved of TPA for 24 h (n = 3 independent experiments).
For all graphs: bars represent means ± SD. See also Figure S3.
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Figure 4. Discovery of AKT and MRTF Dependencies in Cells with Endogenous RAC1P29S
(A) Melanocyte cultures from Rac1WT/WT and Rac1LSLP29S/WT mice were grown in growth factor-reduced medium (FCS 0.25%, TPA-free) and assayed for
viability using CellTiter-Glo; p value using two-way ANOVA for the genotype indicated.
(B) Single-cell suspensions of melanocytes from Rac1WT/WT and Rac1LSLP29S/WT mice (n = 3 independent cultures per genotype) were seeded in soft agar for
3 weeks before imaging and automated counting.
(C) Melanocytes from Rac1WT/WT and Rac1LSLP29S/WT mice were transfected with a custom siRNA library (n = 205 pools), grown in TPA-free medium for 3 days
and assayed for viability (n = 3 independent cultures per genotype, each assayed in three independent experiments).
(D) Detailed plots of the data from the RAC1 effector siRNA screen presented in (C). Control siRNAs (top) and siRNAs that specifically kill melanocytes with
endogenous RAC1P29S (bottom).
(legend continued on next page)
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as a control and was among the top hits in the screen, validating
our experimental system (Figures 4C and 4D). This approach
identified Akt3 and components of the WAVE/ARP2/3/SRF/
MRTF pathway to be specifically required for survival in
RAC1P29S melanocytes. These findings were confirmed using
small molecules targeting AKT, SRF/MRTF, and PAK signaling
(Figure 4E). We observed that inhibition of these pathways had
a cumulative effect on viability, suggesting that SRF/MRTF pro-
motes survival downstream of RAC1P29S by a mechanism
distinct from either AKT or PAK. Interestingly, the flatter and
less dendritic morphology of melanocytes with endogenous
RAC1P29S could be partially reversed with an SRF/MRTF inhibi-
tor (Figure S4E). Of note, depletion of EMT transcription factors
inhibited survival of melanocytes with endogenous RAC1P29S
(Figure S4F), similar to effects observed in melanocytes with
inducible ER-RAC1P29S.
There are insufficient RAC1P29S cases in public clinical
datasets to permit robust statistical analyses (e.g., RAC1P29S
is present in 2/1,020 and 11/366 cases in the Cancer Cell
Line Encyclopedia and The Cancer Genome Atlas [TCGA] mel-
anoma cohort, respectively), so we turned to whole-genome
shRNA screening data from human cancer cell lines (Tsherniak
et al., 2017), which were used to determine co-dependencies in
human cancer cells that require RAC1 for viability. This analysis
demonstrated that RAC1-dependent cancer cells are particu-
larly sensitive to depletion of WAVE complex subunits, ARP2/
3 subunits, and focal adhesion components (Figure S4G).
These results were confirmed in an independent dataset that
was established using a smaller but more specific shRNA li-
brary (McDonald et al., 2017) (Figure S4H). Next, we assessed
a selection of chemical inhibitors in RAC1P29S human mela-
noma cells in an attempt to validate any possible vulnerabilities
uncovered by our earlier studies. Chemical inhibitors may also
help bypass problems of isoform redundancy. We assembled a
panel consisting of seven melanoma cell lines with endogenous
RAC1P29S and seven control melanoma cell lines with RAC1WT
(Figure S4I). First, RAC1 was knocked down to determine its
contribution to the survival of RAC1P29S human melanoma
cells. Knockdown was more harmful to RAC1P29S cell lines
compared with RAC1WT cell lines, in a similar fashion to the dif-
ferential effect of BRAF knockdown in BRAF mutants (Fig-
ure 4F). Subsequently, we selected 16 inhibitors targeting
candidate RAC1 effector pathways and obtained dose-
response viability curves (Figure 4G). Although this approach
is inherently ‘‘noisy’’ due to the significant genetic heterogene-
ity across human melanoma cell lines, we were nonetheless
able to detect a statistically significant sensitivity of RAC1P29S
cell lines to the SRF/MRTF inhibitor CCG-1423, and to the
RAC1 activation inhibitor EHT-1864 (Figure 4H). Interestingly,
RAC1P29S cells tend to be more resistant to the anti-apoptotic
Bcl-2 family inhibitor obatoclax, suggesting that RAC1P29S cells
are generally more resistant to apoptosis (Figure S4J). When
we applied obatoclax and another Bcl-2 family inhibitor, navito-
clax, in mouse melanocytes, RAC1P29S protected against in-
duction of apoptosis (Figures 4I and S4K). This effect appeared
specific to inhibition of the Bcl-2 family anti-apoptotic pathway,
as RAC1P29S did not suppress apoptosis induced by chemo-
therapeutic agents topotecan and etoposide (Figure S4K).
Finally, we tested whether RAC1P29S-specific protection of
apoptosis was mediated through PAK, AKT, or SRF/MRTF.
Combined chemical inhibition of the SRF/MRTF and AKT path-
ways negated protection of obatoclax-induced apoptosis
(Figure S4L).
Taken together, these data suggest that RAC1P29S activates
SRF/MRTF via WAVE and ARP2/3, and also activates AKT, to
suppress apoptosis and promote survival of melanocytes and
melanoma cells (Figure 4J).
RAC1P29S Promotes Tumorigenesis when Expressed
in the Whole Body
We began our investigations of the in vivo effects of RAC1P29S by
inducing its expression in the germline of mice. Crossing
Rac1LSLP29S/WT males and PGK-Cre females with oocytic Cre
expression only produced live offspring with a Rac1WT/WT geno-
type (Figure S5A). Timed analysis revealed that embryos with
germline Rac1P29S/WT displayed general developmental delay,
gross enlargement of the pericardial cavity, and embryonic
lethality 10.5 days post-fertilization (Figures 5A and 5B).
To circumvent embryonic lethality, we generated Rosa26-
CreER+/–;Rac1LSLP29S/WT mice and recombined Rac1LSLP29S
in the whole body of adults by systemic tamoxifen administration
(Figures 5C, S5B, and S5C). Our first clear observation was that
Rac1LSLP29S/WT mice were smaller compared with Rac1WT/WT
littermates, which was dependent on tamoxifen-mediated
recombination (Figures S5D and S5E). After aging animals for
1–2 years, Rac1LSLP29S/WT mice developed splenomegaly and
(E) Effect of combination treatments with inhibitors of the SRF/MRTF, PAK, and AKT pathways on viability of melanocytes with RAC1WT (left) or endogenous
RAC1P29S (right). Mouse melanocyte cultures were grown in regular medium and assayed for viability 72 h after starting drug treatments. Inhibitor doses: CCG-
203971 (SRF/MRTF) 10 mM, G-5555 (PAK) and MK-2206 (AKT) 2 mM.
(F) Effects on viability of humanmelanoma cell lines of reduction in expression of RAC1 or BRAF. Cells were cultured in growthmedium and assayed for viability at
96 h post-transfection (n = 5 cell lines per genotype for the BRAF panel, n = 7 cell lines per genotype for the RAC1 panel, dots represent means of a single cell line
that was tested in multiple independent experiments); p values from t test.
(G) Drug panel targeting RAC1 effectors applied in humanmelanoma cell lineswith RAC1P29S versus cell lineswith RAC1WT. Cells were cultured in growthmedium
and assayed for viability 72 h after starting drug treatments. Drugs ranked by the percentage difference between the half maximal inhibitory concentration (mM) of
RAC1WT cell lines and RAC1P29S cell lines. For each drug, two-way ANOVA was used to probe the full dataset for a genotype effect, which was corrected
according to Benjamini-Hochberg to produce FDR q values; N.D., not determined because curve fitting failed.
(H) Viability of human melanoma cell lines treated with the SRF/MRTF inhibitor CCG-1423 was determined using CellTiter-Glo (n = 7 cell lines per genotype, for
each cell line the mean from two independent experiments was used); statistical analysis was performed as described in (F).
(I) Apoptosis of mousemelanocytes with endogenous RAC1P29S or RAC1WT cultured in growthmedium and treated with obatoclax at 250 nM, 500 nM, or 1 mM for
3 days (n = 2–3 independent cultures per genotype).
(J) Schematic of the SRF/MRTF signaling pathway.
For all graphs: bars represent means ± SD. See also Figure S4.
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tumors, while wild-type controls did not (Figures 5D and 5E). The
tumors were mostly mesenteric lymphomas, occasionally
accompanied by a thymic lymphoma and/or a squamous cell
tumor of the skin (Figures 5F–5H and S5F). Histological and
flow cytometric characterization of the mesenteric lymphomas
demonstrated that the B cell compartment was transformed,
whereas the T cell compartment appeared normal (Figures 5G,
S5G, and S5H).
Thus, ubiquitous expression of RAC1P29S at endogenous
levels in adult mice promotes gradual development of B cell lym-
phoma, while being developmentally lethal when expressed in
the embryo.
A
C D E
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Figure 5. Effect of Ubiquitous Expression of RAC1P29S In Vivo on Induction of B Cell Lymphoma
(A) Schematic of PGK-Cre/Rac1LSLP29S cross and summary of results from the timed analysis of embryos.PGK-Crewas alwaysmaternal to ensure germline Cre
recombination in all embryos. p values derived from chi-square testing are indicated.
(B) Representative micrographs showing gross cardiovascular abnormalities and developmental retardation in Rac1LSLP29S/WT embryos (E10.5). Red arrow,
enlarged pericardial cavity.
(C) Schematic of experimental design to express RAC1P29S in the whole body of adult mice. Tamoxifen was administered by oral gavage.
(D) Representative image of the spleen and quantification of spleen weight in aged mice with the indicated genotype. Bars represent means ± SD (n = 8–13 mice
per genotype); Mann-Whitney test used for statistical comparison.
(E) Tumor-free survival curve of mice with indicated genotypes after treatment with tamoxifen. Result from log rank testing (Mantel-Cox) is indicated.
(F) Representative photos of the digestive tract from a Rosa26-CreER+/–;Rac1WT/WT mouse and a mesenteric lymphoma-bearing Rosa26-CreER+/–;
Rac1LSLP29S/WT mouse. Red arrow, lymphoma.
(G) Representative H&E- and B220-stained sections of a mesenteric lymphoma versus normal mesenteric lymph nodes in a control mouse.
(H) Representative H&E- and B220-stained sections of a normal spleen from a Rosa26-CreER+/–;Rac1WT/WT mouse and the spleen, thymic lymphoma, and
squamous cell tumor of the skin from Rosa26-CreER+/–;Rac1LSLP29S/WT mice.
See also Figure S5.
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Figure 6. Effect of Melanocytic Expression of RAC1P29S In Vivo on Tumorigenesis
(A) Schematic of the Tyr-CreER, BrafCA and Rac1LSLP29S allele combination.
(B) Melanoma-free survival curves of Tyr-CreER+/–;BrafCA/WT;Rac1WT/WT mice and Tyr-CreER+/–;BrafCA/WT;Rac1LSLP29S/WT mice were compared using log rank
testing (Mantel-Cox).
(C) Effects of RAC1P29S on tumor number in Tyr-CreER+/–;BrafCA/WT mice. Groups were compared using the Mann-Whitney test (n = 12–13 mice per genotype).
(D) Schematic of the Tyr-CreER, PtenF, BrafCA, and Rac1LSL-P29S allele combination.
(E) Overall survival curves of Tyr-CreER+/–;PtenF/WT;BrafCA/WT;Rac1WT/WT mice and Tyr-CreER+/–;PtenF/WT;BrafCA/WT;Rac1LSLP29S/WT mice were compared
using the log rank testing (Mantel-Cox).
(F) Effects of RAC1P29S on tumor number in Tyr-CreER+/–;PtenF/WT;BrafCA/WT mice. Groups compared using Mann-Whitney testing (n = 5–9 mice per genotype).
(G) Schematic of the Tyr-CreER, Trp53F, BrafCA, and Rac1LSLP29S allele combination.
(H) Melanoma-free survival curves of Tyr-CreER+/–;Trp53F/F;BrafCA/WT;Rac1WT/WT mice and Tyr-CreER+/–;Trp53F/F;BrafCA/WT;Rac1LSLP29S/WT mice were
compared using log rank testing (Mantel-Cox).
(legend continued on next page)
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RAC1P29S Promotes Melanomagenesis
We did not observe melanomas in mice with RAC1P29S expres-
sion in the whole body, so we proceeded to use the Tyr-CreER
mouse model with topical 4OHT treatment to express RAC1P29S
exclusively in melanocytes in combination with other genetic ab-
errations commonly found in melanoma (Dankort et al., 2009;
Dhomen et al., 2009). First, we mined public sequencing data-
bases to uncover the genomic landscape of RAC1P29S human
cutaneous melanoma. By compiling data from multiple sources,
we identified a substantial number of cases carrying RAC1P29S
(n = 51). In addition, we identified a smaller number of cases
with aRAC1P29Lmutation (n = 5), which is also thought to be acti-
vating (Kawazu et al., 2013; Alan and Lundquist, 2014). In 82%of
RAC1P29S/L cases analyzed there was a co-occurringmutation in
one of the three main melanoma driver genes BRAF, NRAS, and
NF1 (Figure S6A). Rates of BRAF and NRAS hotspot mutations
were similar in RAC1P29S/L melanomas compared with mela-
noma in general, while co-occurrence of NF1-inactivating muta-
tions andRAC1P29S/Lwas significantly enriched in two largemel-
anoma cohorts (cBioPortal cohort, n = 709, log odds ratio 1.73,
p < 0.001; GENIE cohort, n = 1,868, log odds ratio 1.71, p <
0.001). It should be noted that these observations could be influ-
enced by the fact that both RAC1P29S/L and NF1mutations tend
to occur preferentially in highly mutated melanomas carrying a
UV mutational signature (Cancer Genome Atlas Research
Network, 2014).
When we introduced RAC1P29S alone in melanocytes, mice
did not develop melanocytic hyperplasia or melanoma (n =
11 mice, aged for an average of 540 days; Figures 6A and 6B).
In contrast, BRAFV600E alone producedmelanocytic hyperplasia,
which in 4 out of 13 mice progressed to melanoma (aged for an
average of 461 days; Figure 6B). Strikingly, mice with combined
BRAFV600E and RAC1P29S always developed melanoma and the
number of tumors per mouse was significantly increased (n =
12 mice, aged for an average of 394 days; Figure 6C). The
tumor-promoting effect of RAC1P29S was also clearly
observed in BRAFV600E;Pten-hemizygous (Figures 6D–6F) and
BRAFV600E;Trp53-null melanoma models (Figures 6G–6J).
Recombination of the Rac1LSLP29S allele in tumors was
confirmed at both the DNA and mRNA level (Figures S6B and
S6C). In the BRAFV600E;Pten-hemizygous melanoma model we
did not see obvious evidence for loss of the second Pten copy,
either with or without the Rac1LSLP29S allele.
We also evaluated the effect of RAC1P29S in the aggressive
BRAFV600E;Pten-null melanoma model (Dankort et al., 2009).
RAC1P29S did not affect melanoma formation in this setting,
likely due to the already very rapid disease progression in
BRAFV600E;Pten-null;RAC1WT animals (Figures S6D–S6F).
Because RAC1P29S/L- and NF1-inactivating mutations co-occur
in human melanoma, we also elected to cross the Rac1LSLP29S
allele onto a Nf1-null;Trp53-null melanomamodel, which has not
been reported before. In this context, RAC1P29S cooperated with
loss of NF1 and p53 to promote melanomagenesis (Figures
S6G–S6I).
We investigated our two most aggressive mouse melanoma
models to determine if RAC1P29S promotes spontaneous lung
metastasis. Analysis of lungs from both the BRAFV600E;Trp53-
null model and the BRAFV600E;Pten-null model revealed a low
number of lung nodules in Rac1WT/WT mice, which were in part
benign primary bronchoalveolar tumors and in part genuine
melanoma metastases (Figures S6J–S6N). The number of lung
nodules was not significantly increased in Rac1LSLP29S/WT
mice, indicating that RAC1P29S does not promote metastasis in
these models, despite the well-known effects of RAC1 signaling
on cell motility in vitro (Marei and Malliri, 2017).
In summary, we used BRAFV600E- and NF1-loss-driven mela-
noma models to demonstrate that endogenous RAC1P29S pro-
motes the progression of melanocytic hyperplasia to melanoma.
This effect is also seen in the context of loss of PTEN and p53 tu-
mor suppressors.
RAC1P29S Promotes Mesenchymal Differentiation in
Melanomas and Resistance to BRAF Inhibition
To gain a clearer molecular understanding of the effect of
RAC1P29S on the development of primary melanomas we used
the BRAFV600E;Pten-hemizygous model because of the clear
phenotype and access to sufficient RAC1WT control tumors.
Because RAC1P29S promotes the progression of BRAFV600E-
induced melanocytic hyperplasia to melanoma, we considered
that RAC1P29S may achieve this by suppressing oncogene-
induced senescence. However, we could not find clear support
for this hypothesis when evaluating normal skin and tumors for
senescence markers and gene expression signatures (Figures
S7A–S7D).
Pathway enrichment analysis of mRNA sequencing data
showed the presence of SRF/MRTF and mesenchymal signa-
tures in RAC1P29S tumors compared with RAC1WT tumors (Fig-
ures 7A, 7B, S7E, and S7F). In situ hybridization demonstrated
increased mRNA expression of two canonical SRF/MRTF tar-
gets in tumor cells, substantiating the finding of increased
SRF/MRTF signaling in the RAC1P29S melanoma (Figure S7G).
Histologically, the RAC1WT lesions had a relatively uniform cellu-
larity with predominant spindle cells and more compact epithe-
lioid rounded cells in the upper half of the dermis. In contrast,
the RAC1P29S lesions had a neurotized appearance, containing
larger, elongated tumor cells (Figure 7C). An extracellular matrix
gene expression signature was found to be highly enriched in
RAC1P29S tumors compared with RAC1WT tumors, being the
most significant of the 4,838 gene sets in the curated C2 data-
base (Broad) (Figure S7H).
First-line therapy of patients with BRAF mutant melanoma
consists of treatment with a BRAF kinase inhibitor, which often
produces a good initial response before resistance to therapy
rapidly emerges. We studied BRAF inhibitor responses using
(I) Effects of RAC1P29S on tumor number in Tyr-CreER+/–;Trp53F/F;BrafCA/WT mice. Groups compared using an unpaired two-tailed t test (n = 7–9 mice per ge-
notype).
(J) Representative photographs and histology of the dorsal skin of various mouse melanoma models. All mice are Tyr-CreER+/–, with additional alleles indicated.
Time since 4OHT treatment is indicated.
For all graphs: bars represent means ± SD. See also Figure S6.
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Figure 7. Effect of RAC1P29S Drug Resistance and Mesenchymal Phenotype in BRAF-Driven Melanoma
(A) GSEA plot of the EMT hallmark gene set from MSigDB, using RNA-seq data of tumor lysates from Tyr-CreER+/–;PtenF/WT;BrafCA/WT;Rac1LSLP29S/WT mice
versus tumor lysates from Tyr-CreER+/–;PtenF/WT;BrafCA/WT;Rac1WT/WT mice (n = 6 tumors from five to six animals per group).
(B) Normalized mRNA read counts of mesenchymal markers in tumor lysates from Tyr-CreER+/–;PtenF/WT;BrafCA/WT mice. For statistical comparison of groups,
Wald test was applied in combination with Benjamini-Hochberg correction (n = 6 tumors from five to six animals per genotype).
(C) Effect of expression of RAC1P29S in melanoma on tumor architecture. Representative tumor sections shown stained with H&E or melanoma cell markers
S100 and SOX10 (immunohistochemistry).
(D) Tumors were induced in Tyr-CreER+/–;PtenF/WT;BrafCA/WT mice by topical 4OHT. After tumors were established, animals were treated with PLX4720 incor-
porated in chow. Tumor growth curves were compared using two-way ANOVA, with the p value for the genotype effect indicated (n = 18–44 tumors from 6 to
10 animals per data point). Representative photos of tumors are included.
(E) Tumors at the end of the experiment presented in (D) were harvested, lysed and used for immunoblotting with indicated antibodies.
(legend continued on next page)
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the BRAFV600E;Pten-hemizygous melanoma model. RAC1WT
and RAC1P29S tumor growth rates were similar in vehicle-treated
animals, confirming that RAC1P29S does not influence tumor cell
proliferation (Figure 7D). In contrast, the RAC1 genotype had a
significant effect when animals were treatedwith the BRAF inhib-
itor PLX4720. Although RAC1WT tumors were generally stable or
regressed, RAC1P29S tumors were clearly able to grow under
PLX4720 therapy. In line with in vitro data, we did not detect
activation of the MAPK pathway in mutant tumors exposed to
therapy (Figure 7E). Both untreated and inhibitor-treated mutant
tumors had higher expression of the mesenchymal marker
vimentin (Figures 7E and S7I). In the TCGA melanoma cohort,
with or without BRAFmut, RAC1P29S/L mutation, or RAC1 overex-
pression is also associated with relapse (Figures 7F and S7J).
Mouse melanoma cell cultures with RAC1P29S showed lower
levels of apoptosis when exposed to a BRAF inhibitor (Fig-
ure S7K), supporting the idea that the resistance to therapy
observed in our mousemodel resulted from RAC1P29S-mediated
suppression of apoptosis. In an attempt to reverse resistance
to BRAF inhibition, we applied the optimized SRF/MRTF in-
hibitor CCG-257081 (Hutchings et al., 2017). Co-treatment
with CCG-257081 significantly suppressed tumor growth in
PLX4720-treated mice (Figure 7G).
Finally, when we map the impact of RAC1P29S on transcrip-
tional data from our various in vitro and in vivo model systems
against four recently defined, sequential melanoma differentia-
tion states (Tsoi et al., 2018), we see that RAC1P29S induces
de-differentiation from a melanocytic toward an undifferentiated
state, which has been associated with increased resistance to
BRAF inhibitors (Figure 7H).
In summary, endogenous expression of RAC1P29S in BRAF-
driven melanoma produces a less melanocytic and more
mesenchymal differentiation state and generates resistance to
the BRAF inhibitor PLX4720, which can be substantially reversed
by co-treatment with an SRF/MRTF inhibitor.
DISCUSSION
We have investigated the impact of signaling by RAC1, an onco-
gene which is mutationally activated in 4% of melanomas and
may be activated by alterations in upstream regulators in a larger
fraction, showing that RAC1P29S promotes the initiation of mela-
noma driven bymutant BRAF or NF1 loss. Systematic analysis of
effectors reveals that endogenous expression of RAC1P29S acti-
vates PAK, AKT, and also a WAVE/ARP2/3/SRF/MRTF
cascade, which induces switching from a melanocytic to a
mesenchymal-like cellular identity. The end result is that
RAC1P29S cells have enhanced tumorigenic and survival
abilities due to suppression of apoptosis, with the important
consequence that resistance to BRAF inhibitors is generated.
RAC1P29S does not appear to promote melanoma formation
and progression through opposing cellular senescence or by
enhancing the metastatic process.
Our data suggest amodel where RAC1P29S signaling triggers a
transcriptional program that has several effects in melanoma
cells, including suppression of melanocytic differentiation, in-
duction of a mesenchymal-like phenotype, and increased sur-
vival and resistance to therapy. Recently, transcriptional analysis
has been used to define four different interlinked differentiation
states for melanoma subtypes with differential resistance to
drugs, such as BRAF inhibitors, and vulnerability to oxidative
stress (Tsoi et al., 2018). In this analysis, selective pressure
with a BRAF inhibitor promotes transition from a melanocytic/
differentiated state through a transitory state to a neural crest
state, and finally an undifferentiated state. The latter states are
most resistant to BRAF inhibition, but also show increased sensi-
tivity to oxidative stress. When we map the transcriptional data
from our different models, both in vitro and in vivo, we see clearly
that RAC1P29S promotes the adoption of the most undifferenti-
ated and least melanocytic states, which are associated with
BRAF inhibitor resistance. It is also interesting to speculate
whether the known ability of RAC signaling to promote oxidative
stress via its control of NADPH oxidase (Ogrunc et al., 2014)
might suggest that RAC pathway activation could be involved
in the increased vulnerability to oxidative stress of the most un-
differentiatedmelanoma subtypes observed by Tsoi et al. (2018).
Our results suggest that RAC1 signaling promotes a pheno-
typic switch mediated in part by SRF/MRTF to a mesenchymal
differentiation state that is characterized by resistance to
apoptosis induction, possibly mediated through control of the
Bcl-2 family of apoptosis regulators. Investigation of the expres-
sion level of Bcl-2 family proteins in response to RAC1 activation
does not indicate that this control is likely to be attributable to a
single member, but rather an aggregate of gene expression
changes across this family and possibly other apoptotic regula-
tors as well. Because RAC1P29S induces dedifferentiation, it may
be that part of its tumor-promoting potential lies in generating
more progenitor-like cells from which a tumor can be estab-
lished, and in making these cells less sensitive to cell death by
apoptosis, whether this is induced by a deficient microenviron-
ment or therapy with BRAF inhibitor targeting the main driver
oncogene.
Our findings here suggest that the RAC1P29S genotype may
identify patients who are less likely to benefit from BRAF inhibi-
tors. However, the observation that RAC1P29S-driven resistance
to BRAF inhibition can be reversed by inhibiting the SRF/MRTF
transcription factor complex provides a possible approach to
addressing BRAF inhibitor resistance in the clinic. A series of
(F) Influence of RAC1P29S/L mutation status on relapse-free survival in patients with melanoma. Data from the TCGA cutaneous melanoma cohort (n = 309 pa-
tients, 45% BRAFmut and 55% BRAFWT) were used. Groups were compared using log rank testing (Mantel-Cox), with the p value indicated.
(G) After tumors were established by topical 4OHT, animals were treated with PLX4720 incorporated in chow and CCG-257081 by oral gavage. Tumor
growth curves were compared using two-way ANOVA, with the p value for the genotype effect indicated (n = 10–15 tumors from 3 to 4 animals per data point).
(H) GSEA was performed using the four melanoma differentiation state signatures developed by Tsoi et al. (2018), in combination with RNA-seq dataset
of changes in ER-RAC1P29S melanocyte-treated 4OHT (n = 3 independent experiments; left panel), RNA-seq data frommelanocytes with endogenous RAC1P29S
versus RAC1WT (n = 3 independent cultures per genotype; middle panel) and RNA-seq data of tumor lysates from Tyr-CreER+/–;PtenF/WT;BrafCA/WT;
Rac1LSLP29S/WT mice versus Tyr-CreER+/–;PtenF/WT;BrafCA/WT;Rac1WT/WT mice (n = 6 tumors from five to six animals per group; right panel); p values are
indicated.
For all graphs: means ± SD is shown. See also Figure S7.
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SRF/MRTF inhibitors have been developed (Hayashi et al., 2014;
Lundquist et al., 2014) and used extensively in preclinical
models, principally to inhibit fibrosis (Hutchings et al., 2017;
Yu-Wai-Man et al., 2017). The findings reported here suggest
that SRF/MRTF inhibitors, in combination with BRAF inhibitors,
could have utility in the treatment of BRAF mutant melanoma
with an additional RAC1P29S mutation. SRF/MRTF inhibitors
could present an attractive approach to tackling BRAF inhibitor
resistance in melanoma caused by RAC1P29S compared with
the use of RAC inhibitors, which have to date proved difficult
to progress into the clinic (Marei and Malliri, 2017).
Beyond the 4% of melanoma cases with mutant RAC1, it is
also worth speculating whether RAC signaling pathways may
be activated in melanoma and perhaps other tumor types by
different mechanisms, such as alterations in upstream regulatory
proteins such as PREX and TIAM1. If this were the case, then
MRTF pathway inhibition might have a broader potential utility
in countering BRAF inhibitor resistance, and possibly also resis-
tance to other therapeutic agents. RAC1 function is also known
to be essential in KRAS induced tumor formation (Kissil et al.,
2007), and in KRAS oncogene addiction (Yuan et al., 2018), so
the potential exists for SRF/MRTF inhibition to be explored in a
far greater range of tumors than just RAC1P29S melanoma.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
phospho-AKT (T308) CST #13038
phospho-AKT (S473) CST #9271
phospho-AKT (S473) CST #4060
AKT CST #2920
phospho-ERK1/2 (T202/T204) CST #9101
ERK1/2 CST #9107
phospho-PAK1/2 (S199/192) CST #2605
phospho-PAK1/2 (T423/402) CST #2601
PAK1/2/3 CST #2604
phospho-MEK1/2 (S217/221) CST #9145
RAC1 (23A8) Merck Millipore 05-389
Vinculin (hVIN-1) Sigma-Aldrich V9131
Myc (9E10) In-house (CRUK LRI) N/A
Vimentin (EPR3776) Abcam ab92547
N-cadherin CST #13116
c-Jun CST #9165
phospho-c-Jun (S73) CST #9164
ER (MC-20) Santa Cruz sc-542
Fibronectin Abcam ab2413
phospho-BRAF (S445) CST #2696
phospho-CRAF (S338) CST #9427
S100 (4C4.9) Abcam ab4066
SOX10 (A2) Santa Cruz sc-365692
p16 (EPR1473) Abcam ab108349
p27 (F-8) Santa Cruz sc-1641
B220 (RA3-6B2) BD Biosciences 553086
B220-BV510 Biolegend RA3-6B2
CD19-BV605 Biolegend 6D5
CD38-APC Biolegend 90
CD95-BV421 BD Biosciences Jo2
CD138-BV786 BD Biosciences 281-2
NK1.1-PE Biolegend PK136
CD44-APC Ebioscience IM7
CD62L-PeCy7 Ebioscience MEL-14
CD3e-PerCPEFluor710 Ebioscience 145-2C11
CD4-BV421 Biolegend GK1.5
CD8a-FITC Ebioscience 53-6.7
PTEN CST #9559
Chemicals, Peptides, and Recombinant Proteins
4OH-tamoxifen Sigma-Aldrich H6278
Tamoxifen Sigma-Aldrich T5648
CCG-1423 Selleckchem S7719
CCG-203971 Tocris 5277
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
CCG-257081 In-house (MSU) N/A
G-5555 Medchem Express HY-19635
EHT-1864 Tocris 3872
Latrunculin A Tocris 3973
JNK-IN-8 Selleckchem S4901
EHop-016 Selleckchem S7319
CK-666 Sigma-Aldrich SML0006
MK-2206 Selleckchem S1078
CK-869 Sigma-Aldrich C9124
Saracatinib Cambridge Bioscience CAY11497
LGK-974 Selleckchem S7143
Avagacestat Selleckchem S1262
NSC-23766 Tocris 2161
(5Z)-7-Oxozeaenol Tocris 3604
SP-600125 Selleckchem S1460
PF-562271 Abcam ab141360
Obatoclax Selleckchem S1057
Navitoclax (ABT263) Selleckchem S1001
Topotecan Axxora 4100
Etoposide Calbiochem 341205
PLX4720 Plexxicon N.A.
PLX4032/vemurafenib Selleckchem S1267
Critical Commercial Assays
Rac1/Cdc42 Activation Assay Kit Merck Millipore 17-441
RNeasy Mini Kit Qiagen 74104
DNeasy Blood & Tissue Kit Qiagen 69506
RNAscope 2.5 LS Reagent Kit ACDBio 322150
Deposited Data
RNAseq - mouse melanocytes with ER-RAC1P29S GEO repository GSE118349
RNAseq - mouse melanocytes with endogenous RAC1P29S GEO repository GSE118343
RNAseq - mouse melanoma with endogenous RAC1P29S GEO repository GSE118344
Experimental Models: Cell Lines
SK-MEL-2 NCI-60 collection N/A
SK-MEL-5 NCI-60 collection N/A
LOX-IMVI NCI-60 collection N/A
A2058 Francis Crick Institute N/A
Colo-792 ECACC N/A
C32 ECACC N/A
A375 ATCC CRL-1619
WM3060 Coriell Institute WC00126
WM1791C Coriell Institute WC00086
IGR-1 DSMZ ACC-236
YUHEF Ruth Halaban (Yale) N/A
YUSOC Ruth Halaban (Yale) N/A
YURIF Ruth Halaban (Yale) N/A
YUTOGS Ruth Halaban (Yale) N/A
293T Francis Crick Institute N/A
Phoenix-ECO Francis Crick Institute N/A
MCF10A-ECO Francis Crick Institute N/A
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Julian
Downward (Julian.Downward@crick.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Transgenic Mice
All animal experiments were approved by theUKHomeOffice in concordancewith UK and EuropeanUnion law. Ethical approval was
granted by the Animal Welfare and Ethical Review Body of the Francis Crick Institute. All experiments conformed to the relevant reg-
ulatory standards.
The source of all the transgenic mouse strains used are listed in the Key Resources Table. The Rac1LSL-P29S mouse strain
described here has been deposited at Jackson Laboratories as JAX stock number 033790 B6.Cg-Rac1<tm1Jdo>/J. Mice were
kept and bred in the Biological Research Facility of the Cancer Research UK London Research Institute, which subsequently became
the Francis Crick Institute. All strains were kept on a C57BL/6J background. Genotyping was outsourced to an automated genotyp-
ing company (Transnetyx). Mice were euthanized when the cumulative tumor diameter reached 15mmor whenmice displayed signs
of ill health (weight loss, rapid breathing, hunched posture, piloerection, inactivity).
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
melan-a Dorothy Bennett (St. George’s) N/A
XB2 variant Dorothy Bennett (St George’s) N/A
Experimental Models: Organisms/Strains
Rac1LSL-P29S strain Julian Downward Rac1tm1Jdo
PGK-Cre strain (Lallemand et al., 1998) Francis Crick Institute Tg(Pgk1-cre)1Lni
Rosa26-CreER strain (Seibler et al., 2003) Taconic Gt(ROSA)26Sortm9(cre/ESR1)Arte
Tyr-CreER strain (Bosenberg et al., 2006) Jackson Laboratory Tg(Tyr-cre/ERT2)13Bos
BrafCA strain (Dankort et al., 2007) Jackson Laboratory Braftm1Mmcm
Nf1F strain (Zhu et al., 2001) NCIMR Nf1tm1Par
PtenF strain (Lesche et al., 2002) Jackson Laboratory Ptentm1Hwu
Trp53F strain (Marino et al., 2000) Axel Behrens Trp53tm1Brn
Oligonucleotides
pLKO.1-sh-scramble: CCGGGCGCGAT
AGCGCTAATAATTTCTCGAGAAATTAT
TAGCGCTATCGCGCTTTTT
Sigma-Aldrich SHC016
pLKO.1-sh-hRAC1 no. 70: CCGGGCTAA
GGAGATTGGTGCTGTACTCGAGTACAG
CACCAATCTCCTTAGCTTTTT
Sigma-Aldrich TRCN0000004870
pLKO.1-sh-hRAC1 no. 71: CCGGCGCAAAC
AGATGTGTTCTTAACTCGAGTTAAGAACAC
ATCTGTTTGCGTTTTT
Sigma-Aldrich TRCN0000004871
GCACCGGCAGGCAGTAACAGTTCA N/A Rac1-FP5
GTCGTGTAACTGATGAGCAGGCAGGT N/A Rac1-RP5
Recombinant DNA
psPAX2 Paola Scaffidi (Francis Crick Institute) N/A
pMD2.G Paola Scaffidi (Francis Crick Institute) N/A
pcDNA3-2xMyc-HRAS-G12V cDNA Resource Center (Missouri) RASH00MNC0
pLZRS-ER-HRASG12V Paul Khavari (Stanford) Addgene
pBABE-hygro-empty ICRF N/A
pBABE-hygro-2xMyc-Rac1-WT In-house clone 8
pBABE-hygro-2xMyc-Rac1-P29S In-house clone 1
pBABE-hygro-2xMyc-Rac1-Q61L In-house clone 13
pLZRS-ER-Rac1-P29S-shortlinker In-house clone 3
pLZRS-ER-Rac1-Q61L-shortlinker In-house clone 8
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Cell Lines
Cell lines used are listed in the Key Resources Table. Cells were cultured in a humidified incubator at 37C with a controlled
atmosphere of ambient air and 5% or 10% CO2. For all cells, growth medium was supplemented with L-glutamine (4 mM), penicillin
(100 units/ml) and streptomycin (100 mg/ml). Cells were trypsinized using 0.25% trypsin-EDTA and cryopreserved in growth medium
containing 10% dimethylsulfoxide (DMSO; v/v), unless otherwise stated.
Themelan-amousemelanocyte cell line (Bennett et al., 1987) and our own immortalizedmousemelanocyte cultures were grown in
RPMI with 10%FCS and themitogen 12-O-tetradecanoylphorbol-13-acetate (TPA) at 200 nM in 5%CO2. Three days before freezing
and three days after thawing ofmelanocytes, growthmediumwas supplementedwith 200 mMphenylthiourea (PTU) to inhibit pigmen-
tation, which is thought to hinder recovery from cryopreservation (Godwin et al., 2001). Melanocytes were frozen in growth medium
containing 7.5% DMSO.
WM3060 and WM1791C were cultured in MCDB153:Leibovitz L-15 (4:1, v/v), 2% FCS, 1.68 mM CaCl2 and 5 mg/ml insulin in 5%
CO2. YUHEF, YUSOC, YURIF and YUTOGS were cultured in OptiMEM with 5% FCS in 10% CO2. The following cell lines were
cultured in DMEM with 10% FCS in 10% CO2: SK-MEL-2, A2058, C32, A375, IGR-1, 293T, Phoenix-ECO, XB2 and MEFs. The
following cell lines were cultured in RPMI with 10% FCS in 5% CO2: SK-MEL-5, LOX-IMVI, Colo-792. MCF10A cells were cultured
in DMEM:F12 (1:1, v/v) with 5% horse serum, 20 ng/ml EGF, 10 mg/ml insulin and 100 ng/ml cholera toxin in 10%CO2. Finally, mouse
melanoma cells were cultured in Advanced DMEM/F12 (ThermoFisher) with 5% FCS in 5% CO2.
METHODS DETAILS
Molecular Cloning
For cloning of pBABE-RAC1 retroviral expression vectors, we used the pcDNA3.1(+)-2xMyc-HRASG12V construct from the cDNA
Resource Center (Missouri; catalogue number RASH00MNC0) as starting point. HRASG12V was removed using NotI and XbaI restric-
tion sites and replaced with murine RAC1WT cDNA, which was PCR amplified from the pGEX-2T-RAC1 expression vector (Addgene
55692; Fritsch et al., 2013). Site-directed mutagenesis was performed to generate RAC1P29S and RAC1Q61L variants, followed by
Sanger sequencing to confirm successful mutagenesis. The RAC1 sequences plus the N-terminal double Myc-tag were PCR ampli-
fied and inserted into the retroviral pBABE-hygro vector using BamHI and EcoRI restriction sites.
For generating the pLZRS-ER-RAC1 constructs, we used the pLZRS-ER-HRASG12V construct (Addgene 21199) as starting point,
which was a gifted by Dr. Paul Khavari (Stanford). The ER-HRASG12V sequence was sub-cloned into the pcDNA3.1(+) expression
vector (Invitrogen) using BamHI and NotI restriction sites. Next, the majority of the linker plus HRASG12V were cut out by restriction
digestion using EcoRV and NotI. RAC1Q61L cDNA was PCR amplified from our pcDNA3.1(+)-2xMyc-RAC1Q61L expression construct
(see above) and sub-cloned into the digested pcDNA3.1(+)-ER construct using the In-Fusion cloning system (Clontech). This pro-
duced a reading frame that starts with the murine ERa domain containing the G525R mutation, followed by a single aspartic acid
linker that connects to murine RAC1Q61 from the second codon onwards. This construct was used for double site-directed mutagen-
esis (L61Q and P29S) using the QuickChange Lightning Multi-site Mutagenesis kit (Agilent). After confirming mutagenesis by Sanger
sequencing, the ER-RAC1P29S and ER-RAC1Q61L inserts were sub-cloned into pLZRS using BamHI and NotI restriction sites.
PCR amplifications were performed using Primestar HS polymerase (Takara) in combination with oligonucleotides synthesized
by Sigma-Aldrich. DNA purification was performed using QIAquick Gel Extraction and PCR Purification kits from Qiagen.
Restriction enzymes, CIP alkaline phosphatase and T4 ligase were from NEB. XL1-blue and XL-10 gold competent cells (both
from Agilent) were used for transformations and purified DNA preparations were obtained using the Plasmid Miniprep and Maxiprep
kits (Qiagen).
Isolation and Culture of Primary Mouse Melanocytes
We used the detailed protocol developed by others (Godwin et al., 2001). A variant of the mouse keratinocyte cell line XB2 that can
grow without fibroblasts was provided by Dr. Dorothy Bennett (St George’s, University of London). XB2 cells were expanded and
treated with mitomycin C at 8 mg/ml to induce growth arrest. Growth-arrested XB2 cells were seeded in 6-well plates in RPMI
with 10% FCS in 5% CO2 one day before seeding melanocytes to act as ‘feeders’. Neonatal mice aged 2-4 days were euthanized
and tail tissue was collected for genotyping. The dorsal skin was sterilized in 70% ethanol, dissected off from the neck to 5mm above
the tail and transferred to ice-cold PBS. Skins were incubated in PBS with 0.5% trypsin and 1 mM EDTA at 37C for approximately
90-120 minutes. Next, skins were transferred to PBS and the epidermis was split from the dermis using fine forceps and a dissection
microscope. The epidermis waswashed in PBS, transferred to PBS containing 0.025% trypsin and 500 mMEDTA and finely cut using
a scalpel. Trypsin was inactivated using soybean trypsin inhibitor and theminced epidermis wasmixed vigorously and seeded on top
of the XB2 cells in RPMI with 10% FCS, 200 nM TPA and 200 pM cholera toxin. For the initial3 months, cultures were grown under
these conditions and passaged onto fresh XB2 feeders every 1-2 weeks. Medium was replaced twice per week. Cultures were
treated with 4OHT at 1 mM from the first to second passage (9-15 days, depending on the growth rate) to specifically recombine
the Rac1LSL-P29S allele and both Trp53F alleles in melanocytes and not in contaminating cells. Approximately three months after
isolation, proliferation speed increased and cells were cultured without XB2 feeders or cholera toxin, as described in the cell lines
section.
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Isolation of MEFs
Homozygous Rosa26-CreER mice were interbred with heterozygous Rac1LSL-P29S mice in timed matings. Pregnant females were
euthanized between E11.5 and E14.5 to obtain embryos. Heads were used for genotyping. MEFs were isolated and seeded in
6-well plates and cultured as described in the cell lines section. Experiments were performed from the second to fourth passage.
Isolation of Mouse Melanoma Cells
Tumor-bearing Tyr-CreER+/-;Trp53F/F;BrafCA/WT;Rac1WT/WT and Tyr-CreER+/-;Trp53F/F;BrafCA/WT;Rac1LSL-P29S/WT mice were eutha-
nized and tumors were immediately dissected out of the carcass. The epidermis was removed by blunt dissection and deeper, ho-
mogenous tumor tissue was isolated, submerged in 70% ethanol for 5 seconds, rinsed in sterile PBS and placed in PBS on ice. The
tumor was minced using a scalpel and transferred to 1 to 4 ml digestion solution: HBSS supplemented with 75 ng/ml Liberase TM,
75 ng/ml Liberase TH (both from Roche Applied Science) and 50 U/ml DNAse I (Invitrogen). Tumor tissue was digested at 37C for
45 minutes to 1 hr in a shaking incubator at 400 rpm. Next, the suspension was diluted in 10 ml growth medium, mixed vigorously,
spun down, resuspended and seeded in growth medium.
Retroviral Transduction
On the first day, Phoenix-ECO cells were transfected with plasmid DNA using Lipofectamine 2000 (Invitrogen) in antibiotic-free me-
dium. On the second day, medium was refreshed. On the third day, retroviral medium was collected, run through a 0.45 mm filter and
either directly used for target cell infection or frozen on dry ice and stored at -80C. Phoenix-ECO cells received fresh medium
to enable a second virus harvest on the fourth day. MCF10A-ECO cells were infected on two consecutive days using retroviral
medium:growth medium (1:1 or 2:1, v/v), supplemented with polybrene (Merck Millipore) at 10 mg/ml. The morning following the
second infection, medium was replaced with fresh growth medium. Two days after the second infection, cells were trypsinized
and re-seeded in a larger vessel in growth medium supplemented with hygromycin B (ThermoFisher) at 200 mg/ml. Selection was
maintained for four days, at which time mock-infected control cells were completely eradicated.
Lentiviral Transduction
293T cells were co-transfected with pLKO.1-puro shRNA plasmids and the lentiviral packaging plasmids psPAX2 and pMD2.G in
antibiotic-free medium using Lipofectamine 2000. The shRNA sequences are listed in the Key Resources Table. The next day,
medium was refreshed. On the second day post-transfection, lentiviral medium was collected, run through a 0.45 mm filter, frozen
on dry ice and stored at -80C. Fresh medium was added to the 293T cells and a second lentiviral harvest was performed on the
following day. WM3060 target cells were infected with freshly thawed lentiviral medium:growth medium (1:7, v/v), supplemented
with polybrene at 3 mg/ml. Two days post-infection, WM3060 cells were trypsinized and re-seeded in a larger vessel in growth me-
dium supplemented with 2 mg/ml puromycin. Cells were selected in puromycin for two days, at which time mock-infected control
cells were completely eradicated.
siRNA Transfection
siGENOME siRNAs (Dharmacon) were dissolved in siRNA resuspension buffer (Dharmacon) and stored at -80C. On the day of use,
siRNAs were thawed on ice and diluted in HBSS (ThermoFisher) to reach a concentration of 250 nM. Ten ml per well was dispensed
onto 96-well plates (Corning or Nunc, ThermoFisher). This solution was mixed with 10 ml HBSS containing 0.1 ml (for mouse
melanocytes) or 0.15 ml (for human melanoma cells) DharmaFECT 1 transfection reagent (Dharmacon). The transfection complex
was incubated for 20-40 minutes before cells were seeded on top in a volume of 80 ml.
Chemical Inhibitors in Human Melanoma Cell Lines
Drugs and the suppliers from which they were obtained are listed in the Key Resources Table. For the drug treatments, (5Z)-7-
Oxozeaenol, Avagacestat, NSC-23766, CK-869 and CK-666 were applied in an earlier version of our melanoma cell line panel.
This panel contained five RAC1WT cell lines and five RAC1P29S cell lines. Specifically, cell lines A375, SK-MEL-5, YUHEF and YURIF
were not used, as opposed to the full melanoma cell line panel (see Figure S4I). Genotypes for the main melanoma driver genes were
obtained from publicly available sequencing data from the COSMIC database (Wellcome Sanger Institute), the CCLE database
(Broad) and publications (Garman et al., 2017; Krauthammer et al., 2015).
Viability Assays
For the crystal violet assay, cells were washed once with PBS before fixing and staining by submerging themonolayer in crystal violet
solution (0.2% crystal violet, 2% ethanol in H2O) and gently agitating plates for approximately 30 minutes. The monolayer was
washed five times using H2O and dried overnight. Wells were photographed on a flatbed scanner. For quantification, crystal violet
was dissolved in 10% acetic acid and absorbance was measured at 595 nm using a plate reader.
For the CellTiter-Blue assay (Promega), cells were seeded in clear 96-well Nunc plates (ThermoFisher) and cultured in 100 ml
medium. At the end of the experiment, 5 ml CellTiter-Blue reagent was added to each well and plates were returned to their incubator
for 90 minutes. Fluorescence was measured using an EnVision plate reader (PerkinElmer) with an excitation wavelength of 560 nm
and an emission wavelength of 590 nm. The average value of wells containing only medium was subtracted from values of wells
containing cells.
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For the CellTiter-Glo assay (Promega), cells were seeded in black, clear-bottom 96-well plates (Corning) and cultured in 100 ml
medium. At the end of the experiment, 50 ml freshly dissolved CellTiter-Glo lysis buffer was added to each well using a multichannel
pipet and plates were incubated at room temperature on a plate-shaker for twentyminutes. Bioluminescencewasmeasured using an
EnVision plate reader (PerkinElmer).
Apoptosis Assay
Cells were seeded in clear 96-well Nunc plates (ThermoFisher) and cultured in 100 ml medium. Apoptosis induction was determined
using a caspase 3/7 consensus site peptide (Z-DEVD) conjugated to rhodamine 110 (Invitrogen). 100 ml of apoptosis solution (con-
taining 9 mg/ml peptide, 5 mMDTT, 0.1%CHAPS, 25 mMHepes pH 7.3, 1 mM EDTA and 100 mMNaCl) was added to each well and
incubated at room temperature for 5 hr. Fluorescence was measured using an EnVision plate reader (PerkinElmer) with an excitation
wavelength of 485 nm and an emission wavelength of 535 nm. Prior to the determination of apoptosis, relative cell viability of each
well was measured using CellTiter-Blue assay (as described above).
F-actin Staining Assay
Cells were seeded in 8-well tissue culture-treated glass chamber slides (Falcon). Prior to fixation, monolayers were briefly rinsed
twice with pre-warmed PBS and fixed with 3.8% paraformaldehyde (ThermoFisher) in PBS for 10 minutes. Cells were permeabilized
with 0.1% Triton X-100 (Sigma-Aldrich) in PBS for 4 minutes, washed twice with PBS and pre-incubated with 1% BSA (Sigma-
Aldrich) in PBS for 30 minutes. F-actin was visualized with a Leica SP5 inverted confocal microscope following incubation of slides
with approx. 3 nMAlexa Fluor 488 phalloidin (ThermoFisher) in 1%BSA in PBS for 30minutes, twowashes in PBS andmounting with
ProLong Antifade (ThermoFisher). Representative z stack images were taken under oil immersion with a 63x objective.
Sphere Formation Assay
Single cell suspensions were seeded in growth medium containing 0.3% agar on top of a layer of 0.6% agar in 6-well plates. One ml
growth medium was put on top and refreshed every three days. Three weeks after cells were seeded, the growth medium on top of
the agar layers was replaced with 0.1%Giemsa dye in glycerol:methanol (5:24, v/v). Colonies were stained under gentle agitation for
20 minutes. Next, agar was destained by washing five times with H2O for approximately 30 minutes, followed by a sixth wash over-
night. Plates were scanned using a flatbed scanner at 1200 dpi. Grayscale images were opened in ImageJ, a size and intensity
threshold was set to distinguish colonies from background and colonies were counted automatically using the analyze particles
function.
Rac1LSL-P29S Recombination Assay
Genomic DNAwas isolated using theDNeasyBlood & Tissue Kit (Qiagen) and theDNA concentration in the elutewas estimated using
a NanoDrop analyzer (ThermoFisher). Fifty ng DNA was used in a 50 ml PCR reaction using the PfuTurbo DNA polymerase (Agilent) in
combination with Rac1-FP5 and Rac1-RP5 primers (sequences listed in the Key Resources Table), which flank the LSL cassette. We
used the following PCR program: 98C for 1’/ 98C for 30", 66C for 30", 72C for 90" (35 cycles)/ 72C for 10’. The product was
run on a 1.2% agarose gel to separate the 453 bp band corresponding to Rac1WT from the recombined Rac1Lox-P29S band, which is
34 bp larger as a consequence of the single LoxP motif.
Quantitative PCR
Total RNAwas isolated using the RNeasy kit (Qiagen) and eluted in 30 ml H2O. RNA concentrations were estimated using a NanoDrop
analyzer (ThermoFisher). One mg purified RNA was reverse transcribed using the Maxima first strand cDNA synthesis kit
(ThermoFisher) and diluted to a volume of one ml H2O. Four ml of this solution was used in a ten ml qPCR reaction using the Fast
SYBR Green FAST Master Mix (Applied Biosystems) in combination with QuantiTect primer pairs (Qiagen). Reactions were carried
out in 384-well plates using the QuantStudio 7 system (Applied Biosystems). TheDDCtmethodwas used to calculate relative expres-
sion values, which were normalized using the expression of housekeeping genes Gapdh and Tbp.
Immunoblotting
Cells were seeded in 6-well plates. At the end of the experiment, plates were placed on ice,mediumwas aspirated and themonolayer
washed twice with ice-cold PBS before adding 100-150 ml lysis buffer (1% Triton X-100, 50 mM HEPES at pH 7.4, 0.15 M NaCl,
1.5 mM MgCl2, 1 mM EGTA, 0.1M NaF, 10 mM Na pyrophosphate, 1 mM Na3VO4, 10% glycerol, PhosSTOP phosphatase inhibitor
cocktail and EDTA-free cOmplete protease inhibitor cocktail, both added fresh to the lysis buffer and from Roche Applied Science).
Monolayers were incubated on ice in lysis buffer for 10-20 minutes and tilted every two minutes, before scraping with a rubber
policeman and collection of the lysate in pre-cooled microcentrifuge tubes on ice. For tumors, tissue was isolated directly after sacri-
ficing animals. The epidermis was dissected off to ensure pure tumor tissue, which was snap-frozen in liquid N2 and stored at -80
C.
Frozen tumor tissue was then submerged in lysis buffer and immediately homogenized with a microfuge pestle on ice. Lysates were
vortexed for five seconds and spun in a table-top centrifuge at 4C for ten minutes at 21,000 g. The supernatant was transferred to a
new microcentrifuge tube on ice and the pellet was discarded. Protein concentrations were estimated using the Bradford assay
(Bio-Rad) with bovine serum albumin as a standard. NuPAGE LDS lysis buffer (ThermoFisher) was added and lysates briefly vortexed
before incubation at 72C for eightminutes. Lysates were either directly used for SDS-PAGE or stored at -80Cand re-heated directly
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before use. Equal amounts of protein (generally 15-25 mg) were loaded onto NuPAGE 4-12%Bis-Tris protein gels (ThermoFisher) and
SDS-PAGE was performed using Bio-Rad equipment according to the Cell Signaling Technologies protocol (available on their
website). Immunoblots were developed using either the Odyssey Imaging System (LI-COR) or using secondary antibodies
conjugated to horseradish peroxidase (GEHealthcare), before chemiluminescent visualization using standard film or the ImageQuant
LAS 4000 or the Amersham Imager 600 (both from GE Healthcare). Primary antibodies are listed in the Key Resources Table.
PAK1 Binding Domain Pull-Down Assay
The RAC1 activity assay kit from Merck Millipore was used. Cells were seeded in 10 cm dishes (Corning). Growth medium was
replaced with growth factor-reduced medium 24 hr before lysis. For MCF10A cells, this is 1% horse serum without addition of
EGF or insulin. For melan-a, this is growth medium without addition of TPA. At the end of the experiment, monolayers were washed
twice with ice-cold PBS, placed on ice and lysed in MLB supplemented with phosphatase and protease inhibitor cocktails (Roche
Applied Science). Monolayers were scraped off using a rubber policeman and collected in a pre-cooled microcentrifuge tube on ice.
The PAK1 binding domain pull-down assay was performed according to the manufacturer’s protocol and immunoblotting was
performed as described above.
Reverse-Phase Protein Array
Cells were seeded in 6-well plates in full medium. Twenty-four hr before lysis, full mediumwas aspirated, the monolayer washed with
PBS and replaced with medium lacking TPA. To activate RAC1, ER-RAC1P29S melanocytes were treated with 4OHT at 500 nM for
40 hr. Protein lysates (100 ml) were collected and protein concentrations estimated using the Bradford assay. Lysis buffer was added
to reach a final concentration of 1.33 mg/ml. Next, 4X SDS sample buffer was added (40%Glycerol, 8%SDS, 250mMTris-HCL at pH
6.8, plus 10% 2-mercaptoethanol added fresh). Lysates were vortexed, incubated for 5 minutes at 95C and stored at -80C. The
experiment was performed three times on a different day to obtain three independent replicates. Lysates were shipped on dry ice
to the RPPA Core Facility at the MD Anderson Cancer Center, where the reverse-phase protein array (RPPA) was performed accord-
ing to their standardized protocol. In brief, lysates were serially diluted, arrayed on slides with a 2470 Microarray Printer (Aushon
Biosystems) and probed with 300 validated (phospho-)antibodies and biotinylated secondary antibodies. Antibody binding was
measured colorimetrically using tyramide dye. Data were analyzed using Array-Pro Analyzer software (MediaCybernetics) and the
SuperCurve GUI (MD Anderson). To correct for total protein loading, values for individual antibodies were normalized using values
from the entire antibody panel.
RNA-seq of Melanocytes with ER-RAC1P29S
Cells were cultured inmelanocyte growthmedium. Twenty-four hr before lysis, monolayers werewashed oncewith PBS andmedium
was changed to medium lacking TPA. Cells were lysed and total RNA was isolated using the RNeasy Mini Kit (Qiagen). The exper-
iment was performed three times on a different day to obtain three independent replicates. RNA integrity was verified using the RNA
6000 Nano Kit in combination with the 2100 Bioanalyzer (both from Agilent). Next, mRNA libraries were prepared with the KAPA
mRNA Hyper Prep kit (Roche Applied Science) and sequenced as 9-plex pools on the HiSeq 4000 (Illumina). Data were analyzed
as described in the quantification and statistical analysis section.
RNA-seq of Melanocytes with Endogenous RAC1P29S
Mouse melanocytes were isolated and cultured as described in above. Three independent melanocyte cultures from Tyr-CreER+/-;
Trp53F/F;Rac1LSL-P29S/WT mice were used and compared to two independent cultures from Tyr-CreER+/-;Trp53F/F;Rac1WT/WT mice.
Complete recombination of theRac1LSL-P29S and Trp53F alleles was confirmed beforehand. The spontaneously immortalized C57BL/
6Jmelanocyte cell linemelan-a (Bennett et al., 1987) was used as the third independent replicate for theRac1WT/WT group. 24 hr prior
to lysis, cell monolayers were washed with PBS and medium was changed to growth medium lacking TPA. RNA was isolated and
sequenced as described above and data were analyzed as described in the quantification and statistical analysis section.
RNA-seq of Tumor Lysates
Animals were euthanized and tumors harvested. The epidermis was dissected off and a piece of central homogenous tumor tissue
weighing approximately 50 mg was isolated and snap-frozen in liquid N2. Tissue was stored at -80
C prior to lysis by submersion in
RLT buffer (Qiagen), directly followed by homogenization in a microcentrifuge tube using a pestle. RNA was isolated and sequenced
as described above and data were analyzed as described in the quantification and statistical analysis section.
Fluorescence Flow Cytometric Analysis
Animals were euthanized and the spleen andmesenteric lymph nodeswere collected in ice-cold PBS. Tissuewas crushed on top of a
70 mm cell strainer with a plunger from a 5ml syringe and washed through using ice-cold PBS. Cells were spun down at 1500 rpm for
5 minutes at 4C. The supernatant was discarded and the pellet resuspended in FCS:DMSO (9:1, v/v). Cells were stored in cryovials
in liquid N2 until the day of analysis. Before analysis, cells were thawed, washed in ice-cold FACS buffer (PBS with 2% FCS),
resuspended in FACS buffer on ice and counted using a Vi-CELL Counter (Beckman Coulter). Maximum 106 cells were allocated
per well in 200 ml FACS buffer. Cells were washed once, spun down at 2000 rpm for two minutes and stained with 50 ml antibody
cocktail. Antibodies were diluted 1:200 and are listed in the Key Resources Table. Zombie NIR Live/Dead Dye (Biolegend) was
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used to stain for live cells. Cells were stained for 30 minutes at 4C and washed twice in FACS Buffer at 2000 rpm for two minutes at
4C. Samples were kept on ice until acquisition on a BD LSRFortessa analyzer (BD Biosciences). Data were analyzed using
FlowJo 10.
RAC1 Co-dependencies in Human Cancer Cells
Complete gene-level dependency score datasets were obtained from the Project Achilles webportal (Tsherniak et al., 2017) and
directly from Dr. Tobias Schmelzle (Novartis; ATARiS values; McDonald et al., 2017). We identified genes correlating with RAC1 de-
pendency scores by Spearman’s correlation test. Resulting p values were corrected formultiple testing using Benjamini-Hochberg to
obtain an FDR value (threshold 0.05).
Mutational Landscape of RAC1P29S/L Human Melanoma
Whole exome sequencing data of 537 patient melanomas from four large studies (Hodis et al., 2012; Hugo et al., 2016; Krauthammer
et al., 2012; The Cancer Genome Atlas Network et al., 2015) was extracted from cBioPortal. In addition, sequencing data from 607
melanoma cases was obtained from AACR Project GENIE v3.0.0 (AACR Project GENIE Consortium, 2017), also via cBioPortal.
Finally, whole exome sequencing data from eight more RAC1P29S cases was mined directly from publications (Krauthammer
et al., 2015; Wagle et al., 2014) and one RAC1P29S case from the CCLE database (Broad). For the mutation rate analysis of the total
cutaneous melanoma cohort, only the complete datasets from cBioPortal could be used (n = 1144). Tendency towards co-occur-
rence of two mutations within the same tumor was tested via cBioPortal using log odds ratio testing in combination with Fisher’s
exact test. For this purpose, the complete cutaneous melanoma collection on cBioPortal (n = 709) and the AACR Project GENIE
v3.0.0 database (n = 1868) were applied independently.
Publicly-Available Survival Data
Survival data of the TCGA melanoma cohort were obtained from cBioPortal. Relapse-free survival refers to the time from the initial
melanoma diagnosis to relapse. Melanoma tissue for sequencing was not necessarily procured at diagnosis.
Mouse Embryo Analysis
PGK-Cre+/- females were set up with Rac1LSL-P29S/WT males in timed matings. Females were euthanized and embryos quickly
dissected out of the uterus. The yolk sac was used for genotyping. At E8.5, embryos were considered viable if there were no gross
morphological or size abnormalities. From E9.5 onwards, embryos were considered viable if a heartbeat was observed. Embryos
were fixed in neutral buffered formalin (10%) for 24 hr and transferred to 70% ethanol for photography.
Systemic Tamoxifen Treatment
Tamoxifen was dissolved in ethanol at 55C at 300 mg/ml, aliquoted and stored at -80C. At the day of use, aliquots were mixed
with 9 parts (v/v) sunflower oil and gently shaken at 55C until a homogenous solution was obtained. Adult mice were treated with
150 mg/kg tamoxifen by oral gavage on three instances over the course of five days, with a rest day in between treatments. Both
groups contained similar numbers of male and female mice.
Topical 4OHT Treatment
A patch on the central-lower dorsal skin of approximately 3 x 2 cm was shaven the day before treatment. On the day of treatment,
4OHT was freshly dissolved in DMSO at 50 mg/ml. Fifteen ml 4OHT solution was applied to the shaven skin with a pipette and
dispersed using a paintbrush. In this way, animals were treated for three times over the course of seven days, with at least one
rest day in between treatments. Adult male and female mice were used and similarly represented across groups.
Histology
Tissues were fixed in 10% neutral buffered formalin shortly after euthanasia. After 24 to 48 hr, fixed tissues were transferred to 70%
ethanol. Next, tissues were embedded in paraffin and 4 mm sections were mounted on slides. Hematoxylin and eosin (H&E) staining
was performed automatically using a Tissue-Tek Prisma 6132 (Sakura). For S100, SOX10 and B220 immunohistochemistry, antigen
retrieval was performed bymicrowaving in citrate buffer (pH 6.0). Slides were incubated with primary antibodies for 1 hr at room tem-
perature in 1:75, 1:50 and 1:200 dilutions, respectively. For p16 and p27, antigen retrieval was performed bymicrowaving in a 50mM
Tris, 2mMEDTA buffer (pH 9.0). Slides were incubatedwith primary antibodies overnight at a 1:250 dilution for p16 and a 1:50 dilution
for p27. Primary antibodies used are listed in the Key Resources Table.
In situ hybridization was performed using the RNAscope assay according to manufacturer’s instructions (ACDBio). Tissues were
fixed, embedded in paraffin, sectioned and then stained using the RNAscope 2.5 LS Reagent Kit (red) in combination with the BOND
RX automated staining system (Leica Biosystems). For all samples, probes targeting Actr3 and Cyr61 were applied in combination
with PPIB as a positive control and DapB as a negative control.
Mouse Drug Treatment
PLX4720was a gift from Plexxicon. The drug was incorporated into food pellets at 200 ppm (Research Diets, Inc.), resembling clinical
exposure in melanoma patients treated with vemurafenib. The same diet was prepared without PLX4720 for control purposes.
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Tyr-CreER+/-;PtenF/WT;BrafCA/WT;Rac1WT/WT were treated with 4OHT 7 weeks before Tyr-CreER+/-;PtenF/WT;BrafCA/WT;
Rac1LSL-P29S/WT mice to ensure both groups developed tumors and were ready for treatment at the same time. When the majority
of mice had at least one tumor of several mm, regular chow was replaced with either the PLX4720 diet or the control diet. Tumors
were measured every five days using a caliper. Only tumors >2 mm were considered. CCG-257081 SRF/MRTF inhibitor was given
tomice by oral gavage at a dose of 100mg/kg q.d. The drugwas dissolved in a vehicle of 30%PEG, 5%DMSO in phosphate buffered
Saline.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical Analysis
For statistical comparison of two groups, F test was performed to test for equality of variance. If variance of groups was significantly
different, the Mann-Whitney test was used. If not, an unpaired two-tailed t-test was used. To correct for a small number of repeated
tests, Holm-Sidak correction was used. To correct for a large number of multiple tests, we applied Benjamini and Hochberg
correction with the FDR Q value at 5%. To compare two growth curves, two-way ANOVA was performed. To compare read counts
of individual genes in mRNA-seq datasets of two groups, Wald test was used with a Benjamini and Hochberg correction with an FDR
Q value of 5%. Chi-square test was used to statistically assess differences between expected and observed genotypes. To compare
two survival curves, the Mantel-Cox log-rank test was used. Statistical analyses were performed in Prism 7 (GraphPad Software)
or in R.
Unless otherwise stated, on bar graphs and line graphs, values represent means ± SD for n = 3 biological replicates and are
representative of at least three independently repeated experiments.
RNA Sequencing Analysis
Raw reads were quality and adapter trimmed using cutadapt-1.9.1 prior to alignment. Reads were then aligned and quantified using
RSEM-1.2.31/STAR-2.5.2 (Dobin et al., 2013; Li and Dewey, 2011) against the mouse genome GRCm38 and annotation release 86,
both from Ensembl. Differential gene expression analysis was performed in R using the DESeq2 package (Love et al., 2014).
Differential genes were selected using a 0.05 false-discovery rate (FDR) threshold. For gene set enrichment analysis (GSEA), we
used the Java desktop application in combination with pre-ranked gene expression lists that were ordered using the Wald statistic.
To test for enrichment of human gene sets from MSigDB (Broad) in our mouse gene expression data, mouse gene identifiers were
translated to homologous human gene identifiers using the HomoloGene database (NCBI). If there was no human homolog in the
database, the gene was removed from the analysis. SRF/MRTF/TCF target gene sets from Esnault et al. (2014) and Gualdrini
et al. (2016) were murine, hence translation was not required. Due to the great sequencing depth and cellular heterogeneity of the
tumor microenvironment, reads from almost the entire exome were detected in tumor lysates (n = 19750 genes). Many genes
were expressed at very low levels in a single or minority of samples. To focus on biologically relevant genes, our analyses of tumor
lysates only included genes with amean normalized TPM valueR 1 in bothRac1WT/WT andRac1LSL-P29S/WT groups (n = 14460 genes
included in the analysis). Gene expression signatures for senescence (Fridman and Tainsky, 2008), ageing (deMagalhaes et al., 2009)
and E2F targets were obtained from MSigDB (Broad). The SASP signature was obtained from a publication (Coppe et al., 2010).
DATA AND SOFTWARE AVAILABILITY
Messenger RNA sequencing data was deposited to the NCBI Gene Expression Omnibus (GEO) repository (identifiers GEO:
GSE118349, GSE118343, GSE118344). R scripts used to analyse data are available at https://github.com/juliandownward.
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